Welcome to our dedicated page for Nurix Therapeutics news (Ticker: $NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nurix Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nurix Therapeutics's position in the market.
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) receives FDA clearance to introduce new NX-2127 drug product and resume enrollment in Phase 1 study for B-cell malignancies. The company plans to use a new manufacturing process for the drug, aiming to treat patients with cancer more effectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced participation in upcoming conferences by its CFO and CBO. The CFO, Hans van Houte, and CBO, Jason Kantor, will be attending Leerink Partners Global Biopharma Conference on March 12 and Barclays Global Healthcare Conference on March 13, 2024. The fireside chat at the Barclays conference will be webcast live and accessible via the Nurix website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that their CSO, Dr. Gwenn M. Hansen, will present at the AACR 2024 Annual Meeting on next-gen degraders. Dr. Hansen will discuss NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.39%
Tags
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) received FDA Fast Track designation for NX-5948, showing positive Phase 1 results. They licensed a new candidate to Gilead for rheumatoid arthritis and partnered with Seagen. Nurix secured $100 million in capital in 2023, maintaining a strong financial position with $295.3 million in cash and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. announces positive clinical data from the ongoing Phase 1 clinical trial of NX-2127, a BTK and IKZF1/3 degrader, in patients with relapsed/refractory B-cell malignancies at the 65th American Society of Hematology (ASH) Annual Meeting. The data reveal the oncogenic scaffold function of BTK mutations that lack kinase activity and demonstrate that NX-2127 remains susceptible to degradation by NX-2127, showing proof-of-concept therapeutic benefit in chronic lymphocytic leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. (NRIX) receives Fast Track designation from the FDA for NX-5948, a BTK degrader, for the treatment of r/r CLL/SLL. Positive Phase 1 data presented at ASH supports the strategy to develop NX-5948 in CLL and other non-Hodgkin lymphoma indications. The designation is based on encouraging safety and efficacy data from the ongoing Phase 1 clinical trial, with six out of seven patients in the CLL population demonstrating clinical benefit with no dose limiting toxicities or treatment-related serious adverse events. The company plans to accelerate enrollment in the Phase 1 trial of NX-5948 to enable a pivotal study as rapidly as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.56%
Tags
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) presented positive Phase 1 data at the American Society of Hematology, supporting the acceleration of enrollment of NX-5948 in leukemia and lymphoma. The company also highlighted strategic collaborations with Gilead, Sanofi, and Pfizer, generating significant non-dilutive cash flow and building the future pipeline. Nurix plans to expand its therapeutic area focus in autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will present an overview of the company's achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
-
Rhea-AI Summary
Nurix Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: NRIX), presented positive clinical data from its BTK degraders, NX-5948 and NX-2127, at the 65th American Society of Hematology Annual Meeting and Exposition. The data supports the development of these drugs in patients with relapsed or refractory B-cell malignancies, including CLL, MCL, DLBCL, MZL, FL, PCNS, and WM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
Rhea-AI Summary
Nurix Therapeutics, Inc. (Nasdaq: NRIX) to Host Webcast Reviewing Clinical Data from Phase 1 Trials of BTK Degrader Programs NX-5945 and NX-2127
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
Nurix Therapeutics, Inc.
Nasdaq:NRIX
NRIX Rankings
NRIX Stock Data
807.31M
37.68M
2.65%
97.95%
14.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN FRANCISCO
About NRIX
nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe